text:
Document Detail

Pharmacological properties of mifepristone: toxicology and safety in animal and human studies.
MedLine Citation:
PMID:  14698070     Owner:  NLM     Status:  MEDLINE
Roussel Uclaf in partnership with the INSERM unit of Prof. E.E. Baulieu first discovered mifepristone (RU486) as part of a large research program on steroidal compounds with antihormone properties. Exhibiting a strong affinity to the progesterone and the glucocorticoid receptors, mifepristone exerted competitive antagonism to these hormones both in in vitro and in animal experiments. Due to its antiprogesterone activity, it was proposed that mifepristone be used for the termination of early human pregnancy. Mifepristone, at a dose of 600 mg initially used alone, was then used with a subsequent low dose of prostaglandin that led to a success rate of 95% as a medical method for early termination of pregnancy (TOP). Its use was extended to other indications, such as cervical dilatation prior to surgical TOP in the first trimester, therapeutic TOP for medical reasons beyond the first trimester, and for labor induction in case of fetal death in utero. The efficacy and safety of this treatment has been confirmed based on its use for over a decade, with close adherence to the approved recommendations. This paper describes the safety studies conducted in animals as well as the safety follow-up and side effects reported with use of the compound in various indications either approved or unapproved. The rationale for warnings and contraindications for use of the product are also explained. At lower doses, the molecule has proven promising for contraceptive purposes with few reported side effects. However, development of the product for this indication would require long-term studies. Although political and philosophical obstacles have delayed research, the use of mifepristone for other potential indications in gynecology or oncology should be investigated.
Regine Sitruk-Ware; Irving M Spitz
Publication Detail:
Type:  Journal Article
Journal Detail:
Title:  Contraception     Volume:  68     ISSN:  0010-7824     ISO Abbreviation:  Contraception     Publication Date:  2003 Dec
Date Detail:
Created Date:  2003-12-30     Completed Date:  2004-03-19     Revised Date:  2007-11-15
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  United States
Other Details:
Languages:  eng     Pagination:  409-20     Citation Subset:  IM
Center for Biomedical Research, Population Council Regine Sitruk-Ware Center for Biomedical Research, 1230 York Avenue, 6th Floor, New York, NY 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Contraceptives, Postcoital, Synthetic / adverse effects,  chemistry,  pharmacology*,  toxicity
Dose-Response Relationship, Drug
Mifepristone / adverse effects,  chemistry,  pharmacology*,  toxicity
Models, Animal
Progesterone / antagonists & inhibitors
Reg. No./Substance:
0/Contraceptives, Postcoital, Synthetic; 57-83-0/Progesterone; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Summary of evidence and research needs on the use of mifepristone in fertility regulation: consensus...
Next Document:  The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antip...


Content-Type: application/http; msgtype=response

WARC-Type: response

text:
Document Detail

Specifically designed thiosteroids as active-site-directed probes for functional dissection of rat liver cytochrome P450 3A isozymes.
MedLine Citation:
PMID:  1581535     Owner:  NLM     Status:  MEDLINE
Testosterone (T) 6 beta-hydroxylase (6 beta-OHase) is a well-recognized functional marker of rat liver cytochrome P450 3A (P450 3A) isozymes. Pretreatment of rats with inducers or specific or nonspecific inhibitors of P450 3A isozymes is associated not only with stimulation or inhibition of hepatic microsomal T 6 beta-OHase activity but also with parallel changes in the corresponding T 2 beta-, 15 beta-, and 18-OHase activities and T 4,6-diene formation. At the time these studies were conducted, no fully functionally active rat hepatic P450 3A isozymes had been isolated. To determine whether each of these activities was due to a single P450 3A isozyme, or whether multiple isozymes contributed to these activities, we specifically synthesized two thiotestosterone (6 beta- and 2 beta-SHT) analogues as potential mechanism-based inactivators of rat liver T 6 beta- and 2 beta-OHases. In addition, to assess their relative stereoselectivity, 2 alpha-SHT was also included as a control. Our studies revealed that although all three thiosteroids were excellent suicide substrates of P450 3A isozymes, they inactivated these T OHases differentially. Such differential inactivation and determination of the kinetic parameters of inactivation allowed the functional classification of rat hepatic P450 3A isozymes into at least two and possibly three categories: (i) forms (catalyzing 4,6-diene and 6 beta-OHT formation but with characteristically low 6 beta/2 beta-OHase ratios) highly susceptible to inactivation by SHTs; (ii) forms (catalyzing T 6 beta-, 2 beta-, 15 beta-, and 18-hydroxylations with high 6 beta-/2 beta-OHase ratios) moderately susceptible to the SHTs; and (iii) forms somewhat resistant to inactivation, at least at the SHT concentrations tested. Although no specific T OHase could be ascribed to a single P450 3A isozyme, it appears that each of these P450s catalyzed such T regiohydroxylations, albeit at considerably different extents. Furthermore, our studies also revealed that 2 alpha-SHT preferentially inactivated P450 3A forms but surprisingly failed to inactivate rat hepatic P450 2C11, thereby confirming the rather high substrate promiscuity of the P450 3A family of isozymes.
M C Underwood; J R Cashman; M A Correia
Related Documents :
1438345 - Cytochrome p-450 pathway in renal function of normal rats and rats with bilateral urete...
1333795 - Gene synthesis, bacterial expression, and 1h nmr spectroscopic studies of the rat outer...
9253145 - Irgasan dp 300 (5-chloro-2-(2,4-dichlorophenoxy)-phenol) induces cytochrome p450s and i...
4656595 - The effect of exogenous -aminolaevulinate on rat liver haem and cytochromes.
7238685 - The role of the corpus callosum and some subcortical commissures in interocular transfe...
7325015 - An attempt to use central dopaminergic stimulation as a reinforcement for t-maze learni...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, U.S. Gov't, P.H.S.
Journal Detail:
Title:  Chemical research in toxicology     Volume:  5     ISSN:  0893-228X     ISO Abbreviation:  Chem. Res. Toxicol.     Publication Date:    1992 Jan-Feb
Date Detail:
Created Date:  1992-06-18     Completed Date:  1992-06-18     Revised Date:  2007-11-14
Medline Journal Info:
Nlm Unique ID:  8807448     Medline TA:  Chem Res Toxicol     Country:  UNITED STATES
Other Details:
Languages:  eng     Pagination:  42-53     Citation Subset:  IM
Department of Pharmacology, University of California, San Francisco 94143.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Binding Sites
Cytochrome P-450 Enzyme System / antagonists & inhibitors,  metabolism*
Dexamethasone / pharmacology
Isoenzymes / metabolism*
Liver / enzymology*
Magnetic Resonance Spectroscopy
Microsomes, Liver / enzymology,  metabolism
Phenobarbital / pharmacology
Rats, Inbred Strains
Steroid Hydroxylases / antagonists & inhibitors,  metabolism
Sulfhydryl Compounds / chemical synthesis*,  diagnostic use
Testosterone / analogs & derivatives*,  chemical synthesis*,  diagnostic use,  metabolism
Grant Support
Reg. No./Substance:
0/Isoenzymes; 0/Sulfhydryl Compounds; 50-02-2/Dexamethasone; 50-06-6/Phenobarbital; 58-22-0/Testosterone; 9035-51-2/Cytochrome P-450 Enzyme System; EC 1.14.-/Steroid Hydroxylases; EC hormone 6-beta-hydroxylase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In vivo detection and characterization of protein adducts resulting from bioactivation of haloethene...
Next Document:  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiol...

warcinfo:
robots: classic
hostname: ip-10-153-172-175.ec2.internal
software: Nutch 1.6 (CC)/CC WarcExport 1.0
isPartOf: CC-MAIN-2016-36
operator: CommonCrawl Admin
description: Wide crawl of the web for August 2016
publisher: CommonCrawl
format: WARC File Format 1.0
conformsTo: http://bibnum.bnf.fr/WARC/WARC_ISO_28500_version1_latestdraft.pdf


text:
Public Affairs

Congress Agrees to 2011 Budget

Avoiding a government shutdown by about an hour, Congress and the President agreed to a budget to fund the federal government for the rest of the 2011 Fiscal Year on April 8.

The cuts to science funding were far less than was proposed in HR 1, a bill passed by the House of Representatives in February. According to early reports on the budget deal, the following are the impacts to NIH, NSF, and the DOE.

  • NIH will receive $30.6 billion in FY 2011, a $325 million (1.0%) reduction from FY 2010. $210 million of that will be an across- the-board reduction for all Institutes, Centers, and the Office of the Director, $50 million will come from the intramural buildings and facilities account, and another 0.2%, which applies to all nondiscretionary defense spending, has not been determined.
  • NSF will receive $6.8 billion for FY 2011, a cut of $66 million or 1.0% from the FY 2010 budget. The research accounts will be hit with $42 million of that cut and the Education and Human Resources Directorate with $10 million.
  • The DOE Offi ce of Science will receive $4.884 billion, which is $866 million above HR 1 and $20 million below FY 2010. With no earmarks included in the FY11 budget, compared to $76 million worth of earmarks in FY10, the Office actually has an increase of $56 million in unconstrained funds.

Prior to the budget deal, more than 14,000 patients, scientists, health care providers, and supporters of medical research signed an e-petition asking Congress not to cut funding for life-saving research supported by the NIH. The petition, prepared by Th e Ad Hoc Group for Medical Research, of which the Biophysical Society is a member, was created to make Congress aware of public support for NIH funding. The Biophysical Society alerted members about the petition in its monthly legislative update email and on the Biophysical Society Facebook page.

New NIH Diabetes Research Plan

On March 18, 2011, NIH announced a new strategic plan to guide diabetes-related research over the next decade. Developed by a federal work group led by the National Institute of Diabetes and Digestive and Kidney Diseases, the plan calls for continued emphasis on clinical research. The plan, entitled “Advances and Emerging Opportunities in Diabetes Research: A Strategic Planning Report of the Diabetes Mellitus Interagency Coordinating Committee,”focuses on the 10 areas of diabetes research with the greatest potential. These areas include:

  • The relationship between obesity and type 2 diabetes, and how both conditions may be affected by genetics and environment;
  • Autoimmune mechanisms at work in type 1 diabetes;
  • The biology of beta cells, which release insulin in the pancreas;
  • Development of artifi cial pancreas technologies to improve management of blood sugar levels;
  • Prevention of complications of diabetes that aff ect the heart, eyes, kidneys, nervous system, and other organs; and
  • Reduction of the impact of diabetes on groups disproportionately aff ected by the disease, including the elderly and racial and ethnic minorities.

For more information, see the announcement at

New NIH Science Policy Associate Director

Amy Patterson has been named NIH Associate Director of the Offi ce of Science Policy after serving as acting Associate Director since the fall of 2008. Patterson had previously been a postdoctoral fellow at NIH, as well as Deputy Director of the Division of Cellular and Gene Therapies and Senior Medical Officer in the Center of Biologics Evaluation and Research at the Food and Drug Administration. Patterson also serves as Director of the Office of Biotechnology Activities within the NIH Officeof Science Policy, a role that she will continue to fill.

May 2011 Table of Contents


WARC-Truncated: length

text:
Get Our FREE
Industry eNewsletter

Xtent Inc. (XTNT) Announces That It Has Postponed the Special Meeting of Its Stockholders

7/8/2009 7:54:30 AM

MENLO PARK, Calif., July 7 /PRNewswire-FirstCall/ -- XTENT, Inc. today announced that it has postponed its special meeting of stockholders which was scheduled to take place at 9:00 a.m. Pacific Time on Thursday, July 9, 2009. The meeting has been rescheduled for 9:00 a.m. Pacific Time on August 3, 2009.

On May 15, 2009, the Company announced that its board of directors had unanimously approved a Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution"). On June 4, 2009, the Company announced that its board of directors had set July 9, 2009 as the date for a special meeting of the Company's stockholders at which the stockholders would vote on a proposal to approve the Plan of Dissolution.

Since May 15, 2009, members of the Company's management and its bankers, Piper Jaffray & Co., have contacted approximately 11 potential strategic buyers in an effort to secure an investment in or the acquisition of the Company. Eight of the 11 parties indicated that they are not interested in pursuing a transaction with the Company at this time. One of the 11 parties expressed interest in acquiring specific assets of the Company on terms that the Company believes would not maximize the value of the Company's assets. The Company's board of directors decided to postpone the special meeting of its stockholders in order to allow for further discussions with the other two parties.

The discussions with these two parties, and discussions we may have with any other parties, with respect to an alternative to liquidation and dissolution are or will be in the very early stages. We can provide no assurance that these discussions will result in agreement on the terms and conditions of a transaction with either of these two parties or any other party. Even if the terms and conditions of a transaction were agreed to, consummation of the transaction would be subject to one or more risks related to, among others, the due diligence efforts undertaken by either party, the ability to obtain adequate financing, the need for domestic and foreign regulatory approval and approval by the board and stockholders of each party.

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent ("DES") systems for the treatment of coronary artery disease ("CAD"). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

For further information, please visit our website at http://www.xtentinc.com/.

CONTACT: Ronald Austin, General Counsel of XTENT, Inc., +1-650-433-4834,

Web site: http://www.xtentinc.com//

Read at BioSpace.com

comments powered by Disqus


text:
Lotus Pharmaceuticals, Inc. Announces First Quarter Fiscal 2011 Financial Results
5/16/2011 10:37:20 AM

BEIJING, May 16, 2011 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) ("Lotus" or the "Company"), a profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced its financial results for the first quarter ended March 31, 2011. Summary financial data is provided below:

First Quarter Financial Highlights

  • Revenues for the three months ended March 31, 2011 decreased by 12.4% year-over-year to $12.9 million, down from $14.8 million in the first quarter of 2010
    • Wholesale revenues were $8.7 million, or 67.5% of total revenues
    • Retail revenues were $4.2 million, or 32.5% of total revenues
  • Gross profit for the first quarter was $6.2 million, a decrease of 27.7% compared to $8.5 million in the first quarter of 2010. Gross margin was 47.6% and 57.7% for the three months ended March 31, 2011 and 2010, respectively
  • Net income for the quarter decreased 54.7% to $2.2 million, compared to $4.9 million in the first quarter of 2010
  • Earnings per diluted share were $0.08 for the quarter, compared with diluted EPS of $0.18 achieved in the same period a year ago

Mr. Zhongyi Liu, Chairman and CEO of Lotus, stated, "While our first quarter results were impacted by changes in our wholesale segment, our retail sales continue to outperform with 29.1% growth versus the same period in 2010.The substantial increase in the retail segment was driven by our Over-the-Counter Drug Division's sales force.We expect this channel to continue being a major sales growth driver in the coming year. Construction of our Beijing facility continues to progress, and we anticipate additional capacity for growth and significant efficiency improvements once we move into the new building."

Mr. Liu continued, "We plan to focus our capital expenditures in the foreseeable future on the completion of our Beijing facility and our core business in Beijing.Lotus has a well-established nationwide sales and distribution network, strong product development capabilities, and access to capital. Due to the trends of consolidation and increasing regulatory oversight in China's pharmaceuticals industry, we believe these characteristics position Lotus to emerge as an industry leader."

First Quarter Results of Operations

Revenues for the first quarter ended March 31, 2011 were $12.9 million, compared to $14.8 million in the first quarter of 2010.The decrease of 12.4%, or $1.9 million,was primarily due to decreased sales from the Company's wholesale distribution channel, partially offset by strong performance in its retail sales segment.Wholesale revenue decreased 24.2% year-over-year to $8.7 million, or 67.5% of total revenues. Retail revenues increased 29.1% year-over-year to $4.2 million, or 32.5% of total revenues. The growth in retail revenues was primarily attributable to the success of the Company's sales force and new general manager for its Over-the-Counter Drug Division, which served the Company's 10 stores and more than 1,000 other OTC drugstores in Beijing during the quarter.

Gross Profit

Gross profit for the first quarter ended March 31, 2011 was $6.2 millionor 47.6% of total net revenues, as compared to $8.5 million or 57.7% of total net revenues for the quarter ended March 31, 2010. The decrease of 27.7%, or $2.3 million, was primarily attributable to decreased sales and lower margins in the wholesale segment from 2010 to 2011.The decrease in wholesale gross margin was partially offset by higher growth in the lower-margin retail segment.

Income from Operations

Operating income amounted to $2.2 million for the quarter ended March 31, 2011 as compared to operating income of $5.3 million for the first quarter of 2010.The decrease of 57.7%, or $3.1 million, was due largely to decreased gross profit and increased research and development expenses.

Net Income

Net income for the quarter ended March 31, 2011 was $2.2 million as compared to $4.9 million for the quarter ended March 31, 2010, due to the reasons set forth above. Earnings per diluted share were $0.08 for the quarter, compared with diluted EPS of $0.18 for the first quarter of 2010.

Liquidity and Capital Resources

As of March 31, 2011, the Company's current assets were $5.3 million and current liabilities were $7.6 million. Cash and cash equivalents totaled $1.3 million as of March 31, 2011. The Company's shareholders' equity at March 31, 2011 was $93.9 million. The Company generated $3.6 million in cash from operating activities in the first quarter, compared to $2.3 million in the same quarter of 2010.The Company used $3.6 million in net cash for investing activities during the first quarter of 2011, compared to $5.1 million in the first quarter of 2010.

Recent Business Highlights

  • The Company announced that it will add an additional 9,000 square meters (97,000 square feet) to its new headquarters building in Chaoyang District, Beijing. The new construction will contain between 90 and 120 apartments for employees, bringing the total gross area to 34,000 square meters (366,000 square feet). Once completed, this state-of-the-art building will host the Company's GMP manufacturing facility, a storage warehouse, an R&D center, a sales and marketing center, and administrative offices, as well as employee apartments. Currently the exterior furnishing is completed, and the project is moving to the final interior furnishing stage. The Company expects to complete and move into the facility by the end of the year.
  • The Company has stated it plans to make the best use of its land asset in Inner Mongolia. Specifically, management plans to build a 100-mu pharmaceutical distribution center in Inner Mongolia, which is expected to begin construction in 2011 and will provide a base for continued sales into the five northwestern provinces. For the remaining estimated 900 mu of land, the Company intends to make the best use of the asset, including co-developing or selling it to a third party.

Business Outlook for 2011

Management anticipates that 2011 will be a transitional year for Lotus Pharmaceuticals, as the Company will be completing and moving into its new headquarters and shifting its focus to the wholesale business in Beijing and the surrounding areas. After the completion of the headquarters, the Company expects strong growth driven by the wholesale business in Beijing and surrounding areas starting in 2012.

The Company expects total revenue and profitability in 2011 will be lower than that of 2010. Specifically, the revenue from the wholesale segment will down from 2010, driven by the manufacturing disruption of Mu Xin and lower revenue from products with non-exclusive rights. However, management anticipates continued growth in Lotus' retail business in 2011, driven primarily by strong growth in the OTC sales division.

Conference Call and Webcast

Management will host a conference call to discuss these financial results on Tuesday, May 17, 2011 at 10:00 a.m. EDT (7:00 a.m. PDT).

To participate in the call, please dial (877) 941-1430, or (480) 629-9667 for international calls, approximately 10 minutes prior to the scheduled start time.

A replay of the call will be available for two weeks from 1:00 p.m. EDT on May 17, 2011, until 11:59 p.m. EDT on May 31, 2011. The number for the replay is (877) 870-5176, or (858) 384-5517 for international calls; the passcode for the replay is 4442028.

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. is a profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.

At the Company:

Xing Shen, Ph.D.

VP of Corporate Development
Lotus Pharmaceuticals, Inc.

Ph: 415-690-7688

Investor Relations:

Dave Gentry, President

RedChip Companies, Inc.
Tel: +1-800-733-2447, Ext. 104

As of

March 31, 2011

December 31, 2010

$ 1,310,924

$ 1,339,972

Accounts receivable

Prepaid expenses and other current assets

Total Current Assets

Land use right held for development

Deposits and Installments on intangible assets

Land use rights, net

Other intangible assets, net

Total Assets

$ 107,753,324

$ 103,184,615

Accounts payable

$ 32,267

$ 37,829

Other payables and accrued liabilities

Taxes payable

Unearned revenue

Due to related parties

Total Current Liabilities

Due to related parties

Notes payable - related parties


text:
Get Our FREE
Industry eNewsletter

Elekta To Demonstrate The Synergy Of Technology And People At ESTRO 33

4/1/2014 8:54:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free

GenePool newsletter today!

VIENNA, April 1, 2014 /PRNewswire/ -- ESTRO Booth #6200 At ESTRO33, Elekta will demonstrate a comprehensive array of advanced solutions for cancer management. These products include the Versa HD treatment system, Monaco® 5 treatment planning system and Esteya® electronic brachytherapy system for treating skin cancer. ESTRO33 convenes April 4-8 at the Reed Messe Vienna Congress Centre. Follow @Elekta for live tweets from the show floor.

Elekta's theme for this year's ESTRO, The Power of Care, emphasizes the synergy of technology and people working together to support positive patient outcomes. Versa HD embodies this theme through its flexibility, speed and accuracy, in addition to an array of anatomic packages designed to address unique clinical challenges, making it easy to customize a system that meets clinic and patient needs. Versa HD is designed to deliver conventional therapies for indications commonly seen in the clinic, while also permitting treatment of complex cancers that require extreme targeting accuracy.

Medical University Innsbruck is the first center in Austria to begin treating patients with Versa HD. Since January 14, the clinic has put 55 new patients on the Versa HD schedule and is averaging 23 treatments per day, mostly patients with small tumors in the brain and lung.

"The dose rate we're currently using with Versa HD is a factor of up to three times higher than that of the other treatment machines we use here, which helps keep treatment times reasonable in complex cases," says Medical University Innsbruck physicist Paul Eichberger. "The Agility multi-leaf collimator also provides greater precision and its fast leaf speeds increase delivery speed. Because we can conform more closely to the tumor margins, we find we can increase the dose to the tumor while decreasing side effects all within a standard treatment time."

ESTRO will serve as the European launch of Esteya electronic brachytherapy for skin cancer. Esteya, a form of high dose rate (HDR) brachytherapy, brings a miniaturized X-ray source close to the cancerous site, enabling the application of radiation. This direct delivery enables Esteya to focus more therapeutic radiation on the disease target and to minimize radiation to surrounding tissues and organs. Esteya requires only minimal room shielding, allowing the treatment to occur virtually anywhere patients are seen.

Monaco 5 will make its ESTRO debut. The latest version of this advanced treatment planning system consolidates the best of Elekta's treatment planning solutions into a single system and features a new system architecture and graphical user interface.

"Monaco 5 provides us with Segment Shape Optimization for the dynamic MLC, in addition to feet-first orientation of the CT scan, which enables us to set up CT scans for patients who have tumors in the lower abdomen or extremities," says Jens Fleckenstein, PhD, physicist at University Medical Centre Mannheim (Mannheim, Germany). "We also will be able to develop 3D plans, and there are some contouring features such as a pearl tool that allows you to draw freehand contours that are much better in Monaco 5."

Elekta also will highlight Identify, a system utilizing radiofrequency identification (RFID) technology for full confidence in patient and equipment identification during patient setup, thus increasing patient safety. From the moment the patient enters the CT or treatment room, Identify positively verifies the right patient and the accessories required for their treatment.

Elekta lunch symposium

Elekta will host a lunch symposium titled "The Power of Care," on April 5, from 13:00-14:30, at the Reed Messe Vienna Congress Centre in room Lehar 1-2-3, first floor. Presentations will include Versa HD, Monaco 5 and Esteya. During the symposium, three Elekta users will share their knowledge and experience using these latest solutions and how they help improve their ongoing drive toward optimized care.

Learn more at www.elekta.com/ESTRO.

For further information, please contact:

Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, e-mail: michelle.joiner@elekta.com
Time zone: EST: Eastern Standard Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus


text:
About Birch

Communications. Connectivity. Commitment.

Birch is a leading nationwide provider of communications, network, cloud and IT services celebrating 20 years in business (1996-2016). We meet the needs of small, mid-sized, enterprise and wholesale businesses and residential customers by offering a diverse portfolio of integrated technology solutions coupled with a relentless focus on customer service.

Our industry-leading product portfolio includes Metro-Fiber, Metro-Ethernet, unified communications (UC), hosted phone systems, hosted data centers and hosted file storage services. By shifting their technology management to Birch, our customers save valuable time, money and resources.

Our mission is to provide the highest quality service at the best possible value while giving each of our customers the personal attention they deserve.

Our Reach

  • Service spans 50 U.S. states, Washington D.C., Canada and Puerto Rico
  • Nationwide IP-Network with 600 POPs in 22 states
  • 400,000 Metro-Fiber Lit Buildings, Ethernet over Copper, MPLS, VPN
  • 31,000 Fiber Route Miles and 4 Data Centers
  • Business-class products tailored to the needs of our business customers
  • Enterprise-grade SOC2/SOC3 Cloud solutions that are PCI & HIPAA ready
  • Best-in-class Customer Care – award-winning, 24/7/365, U.S. based
  • Diverse, efficient sales channels designed to serve each business segment


text:
The Early Modern Career

Tara Hamling and Tom Lockwood have been awarded funding by the British Academy for a Networking Event on ‘The Early Modern Career’ to be held on Friday 2 May 2014 as part of the activities of the interdisciplinary Research Centre for Reformation and Early Modern Studies.

This symposium will draw together early modern colleagues from across the Midlands Three Cities research partnership to explore through an informal, discussion-based programme the intellectual and institutional contexts in which early modern individuals made their careers, and the ways in which academic professionals might today make their own.

The kind of questions that will be framed, discussed and debated during the event include: What can we determine about early modern career paths? What was the value of specialisation or diversification in the early modern career? What were the mechanics of collaboration in the early modern period and at what stage(s) in their careers did people collaborate? What successes and failures can we identify in case studies of interdisciplinary or collaborative work? What can be identified as ‘Impact’ in the work of early modern artists and writers and how might this inform knowledge exchange and public engagement activities in the present day?

For more information and updates please visit the event website.


text:
Numerology Compatibility

 Numerology Compatibility

Everything in this life is governed by numbers. More and more people are consulting oracles, astrologists and even numerologists to help them predict the future of their business, relationship and even getting a significant other. Numerology is more on finding who you really are based on the name that you have as well as your birth date. There are several aspects as well when it comes to numerology such as lucky date, lucky month and the like, but it all boils down to your name and birth date.

Uses of Numerology Compatibility

When it comes to determining your compatibility with another person, numerologists look to the numbers governing both you and your partner. Keep in mind that your name and birth date has an equivalent numerical value. Following the charts that numerologists keep, they can determine who you would most likely end up with.

Numerology compatibility can play a big role in your life especially when you want to be sure with your partner in business or in love and marriage. There are different kinds of numerology compatibility such as name compatibility or number compatibility. Regardless of what you are using it can still give you an idea on what is playing in your relationship.

One way to determine your compatibility is by finding out your Life path number and Destiny number. In the Life path number you need to convert your birth date into a single number. The Destiny number is determined by converting your full birth name into numbers. Once you have done these two, you will be able to see whether you are made for each other. There are points here where you can find out if you and your partner have differences and how you can work them out together.

Other numerology compatibility deals with the numbers based on your birth date as well as your partners. The goal here is to orient you on what traits you possess and whether you and your partner have any compatible traits or not. Once you have determined this you and your partner have all the necessary tools to guide you to become either closer or find another one that you may be better of with.

Numerology compatibility serves as a guide for you and your partner. Whatever decisions you will be making based on what you have read can change a lot of things. Having an open mind about these things can benefit you in the long run as well.

Related Post


text:
10 New Washington Venues for Meetings and Events

Photo: Courtesy of Muze

Here's a look at the best new Washington restaurants, hotels, party rooms, corporate event venues, conference centers, and private rooms to open this winter. These new and renovated Washington venues can accommodate groups large or small for private and corporate events, meetings, business dinners, cocktail parties, conferences, weddings, and more.

Your email inquiry will be sent to 3 venue